Godavari Drugs logo

Godavari Drugs MD, chairman, board of directors and AGM

BSE: 530317Pharmaceuticals & BiotechnologySmall Cap

Last close ₹120.50down ₹3.65 (2.94%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹124.15.

52-week range of traded prices to 23 Oct 2026
₹69.70Low, 9 Dec 2025₹144.35High, 12 Oct 2026
Market cap
₹122 Cr3,042nd largest listed
P/E
29.3
P/B
1.6
Dividend yield
Nonein the last 12 months
ROE
7.0%
ROCE
4.9%
Debt to equity
1.01
Volume, BSE
6,422

Godavari Drugs board of directors

At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • ChairpersonGHANSHYAM JAJURelated to the promoter
  • Managing directorMUKUND KAKANI

6 directors3 independent2 executive1 non-executive

  • GHANSHYAM JAJU · ChairpersonNon-executive · joined Dec 1987 · reappointed Dec 2022 · 463 months as independent · 1 listed board · 2 committee seats
  • MUKUND KAKANI · Managing directorExecutive · joined Sep 2006 · reappointed May 2022 · 237 months as independent · 1 listed board
  • MOHIT JAJUExecutive · joined May 2010 · reappointed May 2022 · 194 months as independent · 1 listed board · 1 committee seat
  • MAHENDRA UDAY BHALERAOIndependent · joined Nov 2022 · reappointed Dec 2022 · 287 months as independent · 1 listed board · 1 as independent · 3 committee seats, 2 as chair
  • DINESH UDPAIndependent · joined Feb 2024 · 32 months as independent · 1 listed board · 1 as independent
  • SHILPA BUNGIndependent · joined May 2025 · 16 months as independent · 3 listed boards · 3 as independent · 4 committee seats

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

2 directors who left
  • VIMALA BEHRAM MADON, left 23 Jun 2025: Tenure Completion
  • SYED ANIS HUSSAIN, left 23 Jun 2025: Tenure Completion

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 31 Aug 20266 of 6 present3 independent · 16 days in between
    • 14 Aug 20266 of 6 present3 independent · 78 days in between
    • 27 May 20266 of 6 present3 independent
  • Audit Committee

    Chair MAHENDRA UDAY BHALERAO

    MOHIT JAJU, DINESH UDPA

    • 14 Aug 20263 of 3 present2 independent · 78 days in between
    • 27 May 20263 of 3 present2 independent
  • Nomination and remuneration committee

    Chair DINESH UDPA

    GHANSHYAM JAJU, MAHENDRA UDAY BHALERAO

    • 27 May 20263 of 3 present2 independent
  • Stakeholders Relationship Committee

    Chair MAHENDRA UDAY BHALERAO

    GHANSHYAM JAJU, SHILPA BUNG

    • 27 May 20263 of 3 present2 independent

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Jun 2026.

  • Ayyadevara & CoPeer-review certificate valid to Oct 2028

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Godavari Drugs AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Godavari Drugs share news and announcements

Annual general meeting, 25 Sep 2026

7,300 shareholders on the register on 18 Sep 2026; present: 9 promoters and 77 others; votes counted by VIDYA HARKUT / M/s. VSS & Associates.The company's voting result (opens in a new tab)

  1. 1. To receive, consider and adopt the audited standalone financial statement of the Company for the year ended March 31, 2026 together with the reports of the Board of directors and Auditors thereon and RESOLVED THAT the audited standalone financial statements of the Company for the financial year ended March 31, 2026 and the reports of the Board of directors and Auditors thereon, as circulated to the members be and are hereby considered and adopted.MoreLess
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.64%

    Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%

  2. 2. To appoint a director in place of Mr. Ghanshyam Jaju (DIN: 00104601), who retires by rotation and being eligible, offers himself for re-appointment and in this regard to consider and if thought fit, to pass the following resolution as an Ordinary Resolution RESOLVED THAT in accordance with the provisions of section 152 and other applicable provisions of the Companies Act, 2013, Mr. Ghanshyam Jaju (DIN: 00104601), Non-Executive Non Independent Director, who retires by rotation at this meeting and being eligible has offered himself for reappointment, be and is hereby appointed as Director of the CompanyMoreLess
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.64%

    Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%

  3. 3. To ratify the remuneration of Cost Auditors for the financial year ending March 31, 2027 and to consider and, if thought fit, to pass the following resolution as an Ordinary Resolution RESOLVED THAT pursuant to the provisions of Section 148 and all other applicable provisions of the Companies Act, 2013 (Act) and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modifications (s) or re-enactment thereof, for the time being in force), Ms. Bharathula and Associates (Membership no. 13760), Cost Accountants, were appointed by the Board of Directors on the recommendation of the Audit Committee of the Company, to conduct the audit of the cost records of the Company for the financial year ending March 31, 2027, be paid the remuneration as set out in the Statement annexed to the notice convening this meeting. RESOLVED FURTHER THAT the Board of Directors and the Company Secretary of the Company be and are hereby authorized severally to perform all such acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution.MoreLess
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.64%

    Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%

  4. 4. Alteration of Main Objects Clause IIIA of the Memorandum of Association of the Company and to consider and, if thought fit, to pass the following resolution as an Special Resolution RESOLVED THAT pursuant to the provisions of Section 13 and other applicable provisions of the Companies Act, 2013, read with the Companies Incorporation Rules, 2014 including any statutory modifications or re-enactment thereof for the time being in force and subject to such approvals, consents and permissions as may be necessary, consent of the Members of the Company be and is hereby accorded to alter the Main Objects Clause IIIA of the Memorandum of Association of the Company by inserting the following as a new Main Object No. 4 after the existing Main Object No. 3 To manufacture, process, formulate, purchase, sell, import, export, market and distribute nutraceuticals, dietary supplements, health supplements, natural extracts, herbal extracts, botanical extracts, standardised plant extracts, food ingredients, food additives, functional foods and allied products, whether through own manufacturing, third-party contract manufacturing or on loan license basis. RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) be and is hereby authorised to do all such acts, deeds and things and to take all such steps as may be required to give effect to this resolution, including filing of the requisite forms with the Registrar of Companies, Telangana, and to do all things as may be necessary, proper or expedient for the purpose of giving effect to this resolution.MoreLess
    Special
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.64%

    Turnout: all 100.00% · promoters 100.00% · institutions 100.00% · other public 100.00%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
No
The chair is related to the managing director
No
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
No
There was a cyber security incident in the quarter
No

The company's own answers in its filing.

How money raised was used

Reported for the quarter to Jun 2026. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far.

RaisedAmount raisedForSet asideSpentSpent elsewhere
Preferential IssuesMar 202644.12Capital Expenditure for the purpose of manufacturing Active, pharmaceutical Ingredients and intermediates, specialty chemicals in various therapeutic categories including Anti HIV and CNS segments as detailed below: a) Civil construction for production blocks, utilities, platforms, supports, foundations for equipments including finishing consisting of flooring, painting, etc.; b) Procurement and installation of equipments like reactors, heat exchangers, filtration equipments, dryers, pumps, pipelines and fittings, structural steel, safety equipments, fire fighting equipments, enhancement of capacity and upgradation of effluent treatment facilities, etc.; c) Augmenting the electrical infrastructure right from incoming line from substation to transformer and distribution upto the equipments consisting of transformers, electrical pannels, cables, lighting, earthing, etc. Erection and commissioning of all the above110.007.63No
Preferential IssuesMar 202644.12Working Capital Requirement17.120.00No
Preferential IssuesMar 202644.12Repayment of unsecured loans to promoters and / or Directors16.000.00No
₹ crore. Checked by is the agency appointed to monitor how the money is used. The reason and the comments are the company's, its audit committee's and its auditors' own words.